JP2010509369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509369A5 JP2010509369A5 JP2009536520A JP2009536520A JP2010509369A5 JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5 JP 2009536520 A JP2009536520 A JP 2009536520A JP 2009536520 A JP2009536520 A JP 2009536520A JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vegf
- antibody
- use according
- average thickness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 12
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 229960003876 ranibizumab Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86538006P | 2006-11-10 | 2006-11-10 | |
| PCT/US2007/084320 WO2008063932A2 (en) | 2006-11-10 | 2007-11-09 | Method for treating age-related macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509369A JP2010509369A (ja) | 2010-03-25 |
| JP2010509369A5 true JP2010509369A5 (https=) | 2010-12-02 |
Family
ID=39323041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536520A Pending JP2010509369A (ja) | 2006-11-10 | 2007-11-09 | 加齢黄斑変性症を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100111963A1 (https=) |
| EP (1) | EP2089059A2 (https=) |
| JP (1) | JP2010509369A (https=) |
| AU (1) | AU2007323925A1 (https=) |
| CA (1) | CA2666709A1 (https=) |
| WO (1) | WO2008063932A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1802334T3 (pl) * | 2004-10-21 | 2013-01-31 | Genentech Inc | Sposób leczenia wewnątrzgałkowych chorób neowaskularnych |
| MX345039B (es) | 2008-06-25 | 2017-01-16 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles que inhiben el tnfa. |
| LT3216803T (lt) | 2008-06-25 | 2020-06-10 | Novartis Ag | Stabilūs ir tirpūs antikūnai, slopinantys vegf |
| JP2011526892A (ja) * | 2008-06-30 | 2011-10-20 | アンジオブラスト システムズ，インコーポレーテッド | 併用療法を使用した眼疾患及び過剰血管新生の治療 |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| CN102711756A (zh) * | 2010-01-14 | 2012-10-03 | 株式会社三和化学研究所 | 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物 |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| BR112013009701A2 (pt) * | 2010-10-27 | 2016-07-19 | Novartis Ag | regimes de dosagem para o tratamento de doença vascular ocular |
| KR20260004598A (ko) | 2011-01-13 | 2026-01-08 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| WO2012105610A1 (ja) * | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
| US11458199B2 (en) * | 2012-08-21 | 2022-10-04 | Opko Pharmaceuticals, Llc | Liposome formulations |
| KR102083700B1 (ko) * | 2012-08-21 | 2020-03-02 | 옵코 파마슈티칼스, 엘엘씨 | 리포좀 제제 |
| US9802984B2 (en) * | 2013-06-07 | 2017-10-31 | The Johns Hopkins University | Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases |
| EP3054979A1 (en) * | 2013-10-08 | 2016-08-17 | F. Hoffmann-La Roche AG | Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro- 5-trifluoromethyl-benzamide for the treatment of eye diseases |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6835836B2 (ja) * | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
| KR101880670B1 (ko) * | 2015-11-06 | 2018-08-16 | 주식회사 모다이노칩 | 압력 센서를 구비하는 전자기기 |
| PT3384049T (pt) | 2015-12-03 | 2023-08-18 | Regeneron Pharma | Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2018051312A1 (en) * | 2016-09-19 | 2018-03-22 | Lupin Limited | In-line filter for protein/peptide drug administration |
| EP4122486A1 (en) | 2017-11-30 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat diabetic retinopathy |
| JPWO2019151470A1 (ja) | 2018-02-02 | 2021-02-25 | 国立大学法人京都大学 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US190317A (en) * | 1877-05-01 | Improvement in barbers chairs | ||
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| EP1573002A4 (en) * | 2002-02-11 | 2008-07-16 | Genentech Inc | ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION SPEEDS |
-
2007
- 2007-11-09 CA CA002666709A patent/CA2666709A1/en not_active Abandoned
- 2007-11-09 AU AU2007323925A patent/AU2007323925A1/en not_active Abandoned
- 2007-11-09 JP JP2009536520A patent/JP2010509369A/ja active Pending
- 2007-11-09 US US12/514,445 patent/US20100111963A1/en not_active Abandoned
- 2007-11-09 WO PCT/US2007/084320 patent/WO2008063932A2/en not_active Ceased
- 2007-11-09 EP EP07871431A patent/EP2089059A2/en not_active Withdrawn
-
2011
- 2011-09-19 US US13/236,515 patent/US20120009185A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509369A5 (https=) | ||
| JP2022031772A5 (https=) | ||
| Nayak et al. | Montelukast in the treatment of allergic rhinitis: an evidence-based review | |
| JP2015528454A5 (https=) | ||
| JP2014506321A5 (https=) | ||
| JP2017534638A5 (https=) | ||
| NZ596663A (en) | Use of vegf antagonists in intraocular neovascular disease treatment | |
| WO2007049017A3 (en) | Agents that bind a target in pulmonary tissue for treating respiratory diseases | |
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| JP2016520573A5 (https=) | ||
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| JP2017528483A5 (https=) | ||
| RU2017120437A (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| Rotenberg et al. | Redefining the timing of surgery for obstructive sleep apnea in anatomically favorable patients | |
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| WO2017031319A1 (en) | Noradrenergic drug treatment of obstructive sleep apnea | |
| JP2014503593A5 (https=) | ||
| JP2012502103A5 (https=) | ||
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| JP2018530574A5 (https=) | ||
| Singh et al. | Pharmacological treatment of COPD: the devil is always in the detail | |
| JP2022041802A5 (https=) | ||
| Custodio et al. | Lack of clinically relevant effect of bictegravir (BIC, B) on metformin (MET) pharmacokinetics (PK) and pharmacodynamics (PD) | |
| Sockalingam et al. | Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. | |
| JP2019507786A5 (https=) |